Document is current
Any future updates will be listed below
-
Authors
Nogueiras, Ruben https://orcid.org/0000-0002-9976-9930
Nauck, Michael A. https://orcid.org/0000-0002-5749-6954
Tschöp, Matthias H. https://orcid.org/0000-0002-4744-371X
- License Information
-
More Information
Article History
Received: 23 November 2022
Accepted: 24 April 2023
First Online: 12 June 2023
Competing interests
: R.N. declares no competing interests. M.A.N. has been a member on advisory boards or has consulted with Boehringer Ingelheim, Eli Lilly & Co., Medtronic, Merck, Sharp & Dohme, NovoNordisk, Pfizer, Regor, Sun Pharma and Structure Therapeutics (ShouTi, Gasherbrum). M.A.N. has received grant support from Merck, Sharp & Dohme. M.A.N. has also served on the speakers’ bureau of Eli Lilly & Co., Menarini/Berlin Chemie, Merck, Sharp & Dohme, Medscape, Medical Learning Institute and NovoNordisk. M.H.T. is a member of the scientific advisory board of ERX Pharmaceuticals. M.H.T. was a member of the Research Cluster Advisory Panel (ReCAP) of the Novo Nordisk Foundation between 2017 and 2019. M.H.T. attended a scientific advisory board meeting of the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, in 2016. M.H.T. received funding for his research projects from Novo Nordisk (2016–2020) and Sanofi-Aventis (2012–2019). M.H.T. was a consultant for Bionorica SE (2013–2017), Menarini Ricerche S. p.A. (2016) and Bayer Pharma AG Berlin (2016). As former Director of the Helmholtz Diabetes Center and the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018), and since 2018, as CEO of Helmholtz Zentrum München, M.H.T. has been responsible for collaborations with a multitude of companies and institutions worldwide. In this capacity, M.H.T. discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industries and academia worldwide, including, but not limited to, pharmaceutical corporations like Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Medigene, Arbormed, BioSyngen and others. In this role, M.H.T. was/is further responsible for commercial technology transfer activities of his institute(s), including diabetes-related patent portfolios of Helmholtz Zentrum München as, for example, WO/2016/188,932 A2 or WO/2017/194,499 A1.
